Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of IBI302 in Neovascular AMD
NCT04370379Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of efdamrofusp alfa in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by Innovent Biologics. Primary endpoints: Ocular safety assessed by BCVA, slitlamp examination, ophthalmoscopy, IOP, fundus photography at Day 140 and Incidence of adverse events at Day 140. Started May 2020; status: completed.
02
Drugs
efdamrofusp alfa
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04370379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04370379.